Int J Infect Dis. 2022;118:173-182.

Adverse events following COVID-19 vaccination in South Korea between February 28 and August 21, 2021: A nationwide observational study.

, , , ,

제1저자 이동석 · 교신저자 김지원

PMID 35276381 PMC8904009 DOI 10.1016/j.ijid.2022.03.007 IF 4.6 감염내과

소속 (5)

Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea. Electronic address: easeagle@naver.com.
Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea. Electronic address: kjwjor@snu.ac.kr.
Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea. Electronic address: kllee@brmh.org.
Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea. Electronic address: jyj0601@snu.ac.kr.
Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea. Electronic address: gangmali@naver.com.

Abstract

OBJECTIVES To investigate the clinical characteristics of adverse events (AEs) after COVID-19 vaccination in patients in South Korea.

DESIGN Data from the Korean Disease Control and Prevention Agency on AEs from 4 COVID-19 vaccines, including AZD1222, BNT162b2, JNJ-78436735, and mRNA-1273, from February 26, 2021, to August 21, 2021, were assessed. The epidemiological characteristics, clinical symptoms, severity, complications, and mortality were descriptively analyzed.

RESULTS Overall, 36.3 million individuals who completed the COVID-19 vaccination doses during the study period were included, and 153,183 AEs were reported. Most AEs occurred after the first dose (80.6%) and within a day (63.2%) after vaccination. Of the AEs, 95.5% were nonsevere cases; however, 4.5% were severe. Most mild AEs showed a similar frequency across all age groups, but major severe AEs and mortality events increased with age.

CONCLUSIONS Although there were differences in the frequency of occurrence, various adverse reactions were confirmed in using all 4 COVID-19 vaccines, even with the BNT162b2 (Pfizer-BioNTech) vaccine. Caution is needed, and further research should be continuously conducted.

Keywords

COVID-19 vaccinesSARS-CoV-2adverse eventsvaccine reactions

Figures

**Figure 1** Adverse events subgrouping.

**Figure 2** Frequency of AEs after vaccination. The number of AEs was divided by the number of vaccinated people. (A) AEs according to vaccine type and severity. (B) AEs by onset. (C) AEs by age range. Abbreviations: AEs = adverse events.

**Figure 3** Individual cases of AEs after vaccination. The number of AE was divided by the number of vaccinated people. (A) Frequency of mild AEs according to vaccine type. (B) Frequency of major severe AEs and anaphylactic events according to vaccine type. Abbreviations: AEs = adverse events.

**Figure 4** Frequency of AEs according to age range and severity. (A) Mild AEs. (B) Major severe AEs. (C) Anaphylactic events. (D) Mortality events. Abbreviations: AEs = adverse events.

**Figure 5** Frequency of AEs according to sex. (A) Mild AEs. (B) Major severe AEs. (C) Anaphylactic events. (D) Mortality events. Abbreviations: AEs = adverse events.

**Figure 6** Frequency of AEs according to the dose order of the administered vaccine. (A) Mild AEs. (B) Major severe AEs. (C) Anaphylactic events. (D) Mortality events. Abbreviations: AEs = adverse events.

그림 출처: PubMed Central 공개 논문 (PMC8904009)

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

그 밖의 정보